There is more positive news to report on the Ebola subtitling vaccine candidate developed by NUI Galway Hawaii by a scientist Mānoa Axel Lehrer. The prospective vaccine is viable in poor heating conditions for a number of months, which is particularly important in the event that disease outbreaks have commenced so far in rural areas, dispersed in West Africa.
In its scientific article, “Thermostable viruses virus vaccines lyophilized in the presence of aluminum hydroxide,” Lehrer indicates that the vaccine can promote immunization, the ability to stimulate an immune response in the body, after being stored at 104 ° F along up to 12 weeks.
“None of the other Ebola vaccines being developed has the capacity to stand up to high temperatures, which is a constant concern in areas of the world where endemach Filoviruses are present,” said Lehrer, assistant professor in the Tropical Medicine Department, Microbiology. Medical and Pharmacology at UH School of Medicine John A. Burns Mānoa.
“Not only can the ability to stabilize our vaccination candidate maintain immunization, but it cannot reach more people who need them with less vaccine doses. This would be a huge advantage, especially in endemic areas, increasing the number of people receiving enough dose of the vaccine to protect them from disease. ”
Lehrer said that he and his team are very motivated by these preliminary results and look forward to their continued co-operation with Soligenix, a late stage biopharmaceutical company based in New Jersey and Lehrer. HawaiiEbola subunit vaccine co-founder Hawaii Biotech Inc. to further develop vaccines for Ebola and the filovharas.
The paper was published in the Gaeltacht European Journal of Pharmaceutics and Biopharmaceutics.
.Leave a comment